KR20050101554A - 외인성 분자를 일시적으로 또는 안정하게 발현하기 위한발현 카세트 및 발현 벡터 - Google Patents

외인성 분자를 일시적으로 또는 안정하게 발현하기 위한발현 카세트 및 발현 벡터 Download PDF

Info

Publication number
KR20050101554A
KR20050101554A KR1020057014937A KR20057014937A KR20050101554A KR 20050101554 A KR20050101554 A KR 20050101554A KR 1020057014937 A KR1020057014937 A KR 1020057014937A KR 20057014937 A KR20057014937 A KR 20057014937A KR 20050101554 A KR20050101554 A KR 20050101554A
Authority
KR
South Korea
Prior art keywords
sequence
expression cassette
expression
seq
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057014937A
Other languages
English (en)
Korean (ko)
Inventor
윌리엄 피 시스크
홀리 프렌티스
Original Assignee
바이오겐 아이덱 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 아이덱 엠에이 인코포레이티드 filed Critical 바이오겐 아이덱 엠에이 인코포레이티드
Publication of KR20050101554A publication Critical patent/KR20050101554A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Tents Or Canopies (AREA)
  • Paints Or Removers (AREA)
KR1020057014937A 2003-02-14 2004-02-13 외인성 분자를 일시적으로 또는 안정하게 발현하기 위한발현 카세트 및 발현 벡터 Ceased KR20050101554A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44817903P 2003-02-14 2003-02-14
US60/448,179 2003-02-14

Publications (1)

Publication Number Publication Date
KR20050101554A true KR20050101554A (ko) 2005-10-24

Family

ID=32908549

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057014937A Ceased KR20050101554A (ko) 2003-02-14 2004-02-13 외인성 분자를 일시적으로 또는 안정하게 발현하기 위한발현 카세트 및 발현 벡터

Country Status (21)

Country Link
US (2) US7494805B2 (https=)
EP (1) EP1594955B1 (https=)
JP (2) JP2006517802A (https=)
KR (1) KR20050101554A (https=)
CN (1) CN1774500B (https=)
AT (1) ATE553185T1 (https=)
AU (1) AU2004213797B2 (https=)
BR (1) BRPI0407487A (https=)
CA (1) CA2515481A1 (https=)
DK (1) DK1594955T3 (https=)
EA (2) EA008439B1 (https=)
ES (1) ES2384973T3 (https=)
IL (1) IL170178A (https=)
IS (1) IS7974A (https=)
MX (1) MXPA05008523A (https=)
NO (1) NO20054202L (https=)
NZ (1) NZ542316A (https=)
PL (1) PL378110A1 (https=)
RS (1) RS20050614A (https=)
WO (1) WO2004074439A2 (https=)
ZA (1) ZA200506413B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1594955T3 (da) * 2003-02-14 2012-06-25 Biogen Idec Inc Ekspressionskassette og vektor til transient eller stabil ekspression af eksogene molekyler
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
WO2005038020A1 (en) * 2003-10-14 2005-04-28 Biogen Idec Ma Inc. Flp-mediated recombination
CA2559280A1 (en) * 2004-03-15 2005-09-29 Biogen Idec Ma Inc. Methods and constructs for expressing polypeptide multimers in eukaryotic cells using alternative splicing
MY147518A (en) 2004-09-15 2012-12-31 Janssen Pharmaceutica Nv 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
PE20080188A1 (es) 2006-04-18 2008-03-10 Janssen Pharmaceutica Nv Derivados del acido benzoazepin-oxi-acetico como agonistas de ppar-delta usados para aumentar hdl-c, reducir ldl-c y reducir colesterol
WO2008073184A2 (en) * 2006-10-18 2008-06-19 The Scripps Research Institute Genetic incorporation of unnatural amino acids into proteins in mammalian cells
WO2011017319A1 (en) 2009-08-03 2011-02-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of treating disorders associated with protein polymerization
US8809617B2 (en) * 2009-11-05 2014-08-19 The University of Pittsburgh—Of the Commonwealth System of Higher Education Automated high-content live animal drug screening using C. elegans
US9072772B2 (en) 2009-11-05 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating disorders associated with protein aggregation
PH12012501163A1 (en) * 2009-12-21 2019-07-10 Sanofi Aventis Transgenic non-human animal and uses thereof
UY33126A (es) * 2009-12-21 2011-07-29 Sanofi Sa Animal transgénico no humano y sus usos
US8993316B2 (en) 2011-11-16 2015-03-31 Brian P. Hanley Methods and compositions for gene therapy and GHRH therapy
US20150064137A1 (en) 2012-04-17 2015-03-05 Kythera Biopharmaceuticals, Inc. Use of engineered viruses to specifically kill senescent cells
CN104812901B (zh) 2012-09-13 2018-08-10 美国印第安纳大学研究和技术公司 赋予植物抗病性的组合物和系统及其使用方法
AU2013359419B2 (en) 2012-12-10 2018-03-15 Biogen Ma Inc. Anti-blood dendritic cell antigen 2 antibodies and uses thereof
AU2014246731A1 (en) * 2013-03-30 2015-11-19 Usha Biotech Limited Methods and constructs for expressing biologically active proteins in mammalian cells
JP6581969B2 (ja) * 2014-04-24 2019-09-25 アキュルナ株式会社 タンパク質発現を向上させる方法およびタンパク質発現用組成物
TWI747098B (zh) 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
US11415263B2 (en) * 2020-03-20 2022-08-16 Edwards Vacuum Llc Conversion kit for a support frame, a support frame and an integrated vacuum system mounted in a support frame

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8717430D0 (en) * 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ES2198025T3 (es) 1991-10-25 2004-01-16 Immunex Corporation Anticuerpos contra cd40-l.
AU678154B2 (en) 1992-04-02 1997-05-22 Sembiosys Genetics Inc. Oil-body protein cis-elements as regulatory signals
AU698739B2 (en) 1995-06-06 1998-11-05 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
IL122174A (en) 1995-06-07 2004-07-25 Immunex Corp Dna encoding a cd40l mutein and a cd40l polypeptide encoded by said dna
US5985662A (en) 1995-07-13 1999-11-16 Isis Pharmaceuticals Inc. Antisense inhibition of hepatitis B virus replication
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
EP0914441A2 (en) * 1996-04-23 1999-05-12 The Wistar Institute Of Anatomy And Biology Novel human cytomegalovirus dna constructs and uses therefor
AU8589998A (en) 1997-07-24 1999-02-16 Valentis, Inc. Ghrh expression system and methods of use
AU2324999A (en) * 1998-01-16 1999-08-02 California Pacific Medical Center Research Institute Methods and compositions for gene delivery
EP0953639A1 (en) * 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US6455677B1 (en) * 1998-04-30 2002-09-24 Boehringer Ingelheim International Gmbh FAPα-specific antibody with improved producibility
WO1999061066A2 (en) * 1998-05-27 1999-12-02 Avigen, Inc. Convection-enhanced delivery of aav vectors
EP1092768A1 (en) * 1999-10-16 2001-04-18 ARTEMIS Pharmaceuticals GmbH Conditional gene trapping construct for the disruption of genes
EP1292686A1 (en) 2000-06-07 2003-03-19 Smittskyddsinstitutet Gene expression cassette and its use
JP2004502426A (ja) 2000-07-05 2004-01-29 トランジェーヌ、ソシエテ、アノニム 平滑筋の発現を制御するキメラプロモーター
JP2002233374A (ja) * 2001-02-06 2002-08-20 Japan Science & Technology Corp 遺伝子導入及び／又は遺伝子欠損非ヒト動物作製用ベクター
DE10133407A1 (de) 2001-07-13 2003-01-23 Basf Ag Expressionskassetten zur transgenen Expression von Nukleinsäuren
US20030235823A1 (en) * 2002-06-24 2003-12-25 The University Of Alabama Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation
DK1594955T3 (da) 2003-02-14 2012-06-25 Biogen Idec Inc Ekspressionskassette og vektor til transient eller stabil ekspression af eksogene molekyler

Also Published As

Publication number Publication date
NO20054202D0 (no) 2005-09-09
IL170178A (en) 2011-12-29
EP1594955A4 (en) 2006-07-19
JP2006517802A (ja) 2006-08-03
PL378110A1 (pl) 2006-03-06
ATE553185T1 (de) 2012-04-15
BRPI0407487A (pt) 2006-02-14
MXPA05008523A (es) 2005-10-20
ZA200506413B (en) 2006-04-26
NZ542316A (en) 2006-04-28
CN1774500B (zh) 2011-03-02
EP1594955B1 (en) 2012-04-11
AU2004213797B2 (en) 2009-09-17
WO2004074439A9 (en) 2004-12-23
IS7974A (is) 2005-08-11
DK1594955T3 (da) 2012-06-25
US20060141625A1 (en) 2006-06-29
RS20050614A (sr) 2007-12-31
WO2004074439A2 (en) 2004-09-02
EA200501296A1 (ru) 2006-04-28
WO2004074439A3 (en) 2004-10-28
EA200700469A1 (ru) 2008-10-30
US20100158879A1 (en) 2010-06-24
US7494805B2 (en) 2009-02-24
CA2515481A1 (en) 2004-09-02
EA008439B1 (ru) 2007-06-29
JP2010213718A (ja) 2010-09-30
EP1594955A2 (en) 2005-11-16
HK1084690A1 (en) 2006-08-04
NO20054202L (no) 2005-11-11
AU2004213797A1 (en) 2004-09-02
CN1774500A (zh) 2006-05-17
ES2384973T3 (es) 2012-07-16

Similar Documents

Publication Publication Date Title
CN1774500B (zh) 用于瞬时或稳定表达外源分子的表达盒和载体
AU2018236725B2 (en) Adeno-associated virus virions with variant capsid and methods of use thereof
AU2015263150B2 (en) Lentiviral vectors
US9163219B2 (en) Single expression vector for generation of a virus with a segmented genome
CN101541968B (zh) 重组宿主细胞中的脱氧核糖核酸酶表达
CN112552380B (zh) 一种SARS-CoV-2病毒的免疫原及其应用
JP2006517802A5 (https=)
CN110904155B (zh) 一种碱基编辑器及其制备方法和应用
CA2504595A1 (en) Intron fusion construct and method of using for selecting high-expressing production cell lines
CN113583978A (zh) 3种重组腺病毒以及SARS-CoV-2 Spike蛋白的RBD以及它们的应用
US20030232414A1 (en) Hybrid vector having a cytomegalovirus enhancer and myeloproliferative sarcoma virus promoter
CN102154368B (zh) 一种组织特异性兼可调控性慢病毒基因表达载体
CN107090473A (zh) 抗菌肽pr39和pg1共表达载体和转pr39和pg1基因小鼠制备方法
US20240082327A1 (en) Retroviral vectors
CN114181318B (zh) 一种组织特异性表达穿透血脑屏障的idua融合蛋白的重组腺相关病毒及应用
CN109929864A (zh) 核苷酸序列tWPRE及其基因表达载体和应用
EP2589661A1 (en) Posttranscriptional Element
HK1084690B (en) An expression cassette and vector for transient or stable expression of exogenous molecules
HK1122837A (en) Treatment of disease using an improved regulated expression system
NO845186L (no) Vektorsystem for innfoering av heterolog dna i eykaryotiske celler.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050812

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20090210

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110216

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110503

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110216

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I